P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor

RCT (n=2993) found that 3-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy provided similar rates of a composite endpoint (all-cause death, myocardial infarction or stroke at 12 months) vs 12 months DAPT (3.0% for both, HR 1.02).

SPS commentary:

There was also no difference in the primary endpoint for 3 months vs 12 months DAPT when a more potent P2Y12 inhibitor was used (i.e. prasugrel and ticagrelor).

Heart